COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Chinese study reveals how single cells develop into whole plants
- PKU vice-president under probe for violations of Party disciplines and laws
- Giant floral basket, displays to decorate National Day
- China issues first standard for medical devices based on BCI technology
- Hong Kong to further accelerate development of Northern Metropolis
- China honors outstanding contributors to care of next generations
